Please replace the paragraph that begins on page 20, line 2, with the following rewritten paragraph:

-- Endoglucanase RCE II of the invention is an enzyme having the amino acid sequence spanning from position 1 to position 343 of SEQ ID NO: 3 and having endoglucanase activity. The amino acid sequence spanning from position -23 to position -1 of SEQ ID NO: 3 or a part thereof may be added to the N-terminus of the above protein. The polypeptide to which this sequence is added is included within the invention as a modified peptide of endoglucanase RCE II. Since this amino acid sequence spanning from position -23 to position -1 is believed to be a signal peptide, a part of the sequence means a partial sequence retaining the signal peptide activity as well as a sequence remaining at the N-terminus as a result of some difference that occurred in the site of processing depending on the type of the host. --

B2

Please replace the paragraph that begins on page 20, line 20, with the following rewritten paragraph:

-- Endoglucanase RCE III of the invention is an enzyme having the amino acid sequence spanning from position 1 to position 337 of SEQ ID NO: 5 and having endoglucanase activity. The amino acid sequence spanning from position -23 to position -1 of SEQ ID NO: 5 or a part thereof may be added to the N-terminus of the above protein. The polypeptide to which this sequence is added is included within the invention as a modified peptide of endoglucanase RCE III. Since this amino acid sequence spanning from position -23 to position -1 is

B3

believed to be a signal peptide, a part of the sequence means a partial sequence retaining the signal peptide activity as well as a sequence remaining at the N-terminus as a result of some difference that occurred in the site of processing depending on the type of the host. --

B3

Please replace the paragraph that begins on page 45, line 5 from the bottom of the page, with the following rewritten paragraph:

-- To express RCE I gene in yeast, the following investigations were done using the host-vector system as described in WO97/34004 specification. --

B4

Please replace the paragraph that begins on page 51, penultimate line, with the following rewritten paragraph:

-- Expression of RCE II gene in yeast was carried out according to the method of Example B7 (2). Thus, the plasmid pRCEII-Bgl obtained in Example C4 (1) was digested with BglII and the endoglucanase RCE II gene was recovered. This gene was operably ligated into BamHI site, i.e., downstream from glyceraldehyde-3-phosphate dehydrogenase (GAP) promoter, of plasmid vector pY2831 to yield a plasmid pYRCEII. This plasmid was used to transform yeast (*Saccharomyces cerevisiae*) strain MS-161 (MATa, trp1, ura3) according to WO97/34004 specification to yield a transformant in which the endoglucanase RCE II was capable of expression. --

B5

Please replace the paragraph that begins on page 77, line 9 from the bottom of the page, with the following rewritten paragraph:

-- The mutant RCE I gene was expressed in yeast according to the method of Example B7 (2). Thus, the plasmid pMCEI-G obtained in Example E3 (1) was digested with EcoRI and a mutant MCE I gene was recovered. This gene was operably linked to the EcoRI site downstream from glyceraldehyde-3-phosphate dehydrogenase (GAP) promoter of plasmid vector pY2831 to yield a plasmid pYMCEI. This plasmid was used to transform yeast (*Saccharomyces cerevisiae*) strain MS-161 (MATa, trp1, ura3) according to WO97/34004 specification. Thus, a transformant was obtained in which the endoglucanase MCE I could be expressed. --

IN THE CLAIMS:

Please replace claim 84 with the following rewritten claim:

-- 84. (Twice Amended) A method of deinking a waste paper, comprising a step of treating the waste paper where the enzyme, protein, modified protein or homologue according to claim 1 in the presence of a deinking agent. --

REMARKS

In the foregoing amendment, the specification was amended to (1) correct editorial errors, (2) identify the parent application, and (3) state that the parent application was not published in English at the time of the filing of this US national stage application. Claim 84 was amended to correcting a typographical